Objective: To assess the relationship between posttraumatic brain injury statin use and (1) mortality and (2) the incidence of associated morbidities, including stroke, depression, and Alzheimer's disease and related dementias following injury. Setting and Participants: Nested cohort of all Medicare beneficiaries 65 years of age and older who survived a traumatic brain injury (TBI) hospitalization during 2006 through 2010. The final sample comprised 100 515 beneficiaries. Design: Retrospective cohort study of older Medicare beneficiaries. Relative risks (RR) and 95% confidence interval (CI) were obtained using discrete time analysis and generalized estimating equations.
1,2
In addition to an increase in mortality for older adults, there also is a chronic neuroinflammation following injury. This sustained inflammatory cascade can potentially lead to several unfavorable outcomes including stroke, depression, and Alzheimer's disease and related dementias (ADRD), and studies have indicated these associations. [3] [4] [5] [6] [7] [8] These sequelae of TBI can occur in the days, months, and years following TBI. 4, 9, 10 It should be noted that while these morbidities are linked to TBI, these morbidities can occur naturally among older adults as aging also contributes to chronic neuroinflammation. Therefore, older adults with TBI are particularly susceptible to both chronic neuroinflammation and ensuing sequelae of TBI. E69 disease, as a potential therapy for TBI and its sequelae because statins may help reduce chronic neuroinflammation and increase cerebral blood flow following TBI. 15, 16 No study has investigated the relationship between statin use following TBI and mortality or associated morbidities. Thus, the primary objective of this study is to assess the relationship between post-TBI statin use mortality. A secondary objective is to examine the relationship between post-TBI statin use and the development of TBI sequelae, including stroke, depression, and ADRD among older Medicare beneficiaries.
METHODS

Study sample
The Chronic Condition Data Warehouse (CCW) from the Centers for Medicare & Medicaid Services was used to investigate the relationship between post-TBI statin use and mortality or associated morbidities following TBI. TBI was identified by inpatient claims using the 01 . Beneficiaries' first admission date for TBI during this time period is defined as the index date/index TBI. Any TBI occurring within 14 days of a previous TBI was collapsed and classified as a single TBI event due to the possibility of multiple TBI claims within 14 days being for the care for a single TBI event. 6, 7 Beneficiaries were required to be at least 65 years of age at the time of TBI, have 6 months of observation time prior to TBI, and continuous coverage of Medicare parts A, B, and D throughout the study period following TBI. Therefore, beneficiaries could have up to 54 months of follow-up. Beneficiaries with Medicare part C (private insurance) were excluded because their inpatient, outpatient, and medication claims were not available.
Exposure
The exposure of interest was use of statins, including atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. Individual and any statin use was determined per 30-day period (henceforth referred to as month) prior to and following TBI. Beneficiaries were required to have either a claim for a filled statin prescription or a proportion of days covered of greater than 0 in a month to be classified as statin users in a particular month. This approach has previously been used in pharmacoepidemiology studies using Medicare claims data. 17, 18 Proportion of days covered was calculated by dividing the number of days' supply a statin was available during a month by the number of days in a month (30 days). Since beneficiaries had 6 months of coverage prior to TBI, pre-TBI statin use was divided into 4 categories: (1) use in the first or second month immediately prior to TBI; (2) use that was 3 or 4 months prior to TBI; (3) use that was more than 4 months prior to TBI; and (4) no use prior to TBI. Following TBI, beneficiaries were classified as users or nonusers on a monthly basis, creating a time-varying exposure.
Outcomes
The two outcomes of interest included mortality and TBI sequelae (stroke, depression, or ADRD). While there are several morbidities associated with TBI, this study focused on stroke, depression, and ADRD. These associated morbidity outcomes are studied because of their prevalence and ease of identification in claims data. Mortality was assessed following hospital discharge, making the outcome all-cause mortality rather than TBIspecific. Different variables were created to assess 30-day, 60-day, 90-day, and mortality at any time following TBI hospitalization discharge. The 30-day, 60-day, and 90-day mortality variables were mutually exclusive to examine the time period for when statin use may have been protective for primary injury. Beneficiaries who died within 30 days were excluded when analyzing 60-day or 90-day mortality to avoid biasing the results.
Stroke was defined by inpatient claims using ICD-9 codes 430.xx-432.xx (hemorrhagic stroke) and 433.xx, 434.xx, 435.xx, 437.0x, 437.1x (ischemic stroke). Depression and ADRD were defined through the CCW flags for chronic conditions. Beneficiaries with their first diagnosis of depression or ADRD following TBI were flagged as having incident depression or ADRD, respectively.
Covariates
This study incorporated covariates including sociodemographic, health, drug utilization, and geographical characteristics using CCW and Area Health Resource File data. Chronic Condition Data Warehouse data included demographic characteristics, chronic conditions, and injury severity. Injury severity covariates included length of hospital stay, discharge status, and TBI injury severity, determined by the ICD-9-CM-based independent survival risk ratio measure.
In addition to pre-TBI statin use, drug utilization covariates included anticoagulant, antiplatelet, and β-blocker use per month following TBI. These pharmacotherapies were included because they may impact mortality and associated morbidities or have been indicated as potential treatments for TBI. [19] [20] [21] [22] Area Health Resource File data were linked to CCW data by beneficiaries' county codes and included deE70 JOURNAL OF HEAD TRAUMA REHABILITATION /NOVEMBER-DECEMBER 2018
Data analysis
Bivariate analyses examining associations between statin use and demographic, health, and geographic characteristics were tested using χ 2 test of proportions for categorical variables, Student t tests for continuous variables, and the Wilcoxon rank sum test when comparing medians between statin users and nonusers.
Given the longitudinal nature of the data, discrete time analysis was used to assess the relationship between statin use and mortality and associated morbidities. This relationship was assessed using generalized estimating equations with a binomial distribution and complimentary log-log link. This modeling approach is appropriate for survival analysis, given multiple observations per beneficiary and a time-varying exposure. 24 Statin use was lagged one month for TBI sequelae outcomes to ensure the exposure preceded the outcome.
18,24 Statin use was not lagged for the mortality models because observation time for beneficiaries ends at death; therefore, mortality will always follow the exposure. This is not necessarily true for beneficiaries who experience TBI sequelae events because beneficiaries are censored following the month an event is experienced. For instance, it is possible that a beneficiary experiences an event in the beginning of the month and continues to receive statins in the same month following the event. In such cases, without lagging, the outcome precedes the exposure. Separate generalized estimating equations models were used for each outcome and each beneficiary was censored after experiencing the outcome of interest.
All final models included sociodemographic variables (age, race, sex, county-level income, low-income subsidy per month, and region); comorbidities (hyperlipidemia, hypertension, congestive heart failure, ischemic heart disease, acute myocardial infarction, ADRD, valvular heart disease, and diabetes); count of CCW chronic conditions, excluding the aforementioned comorbidities due to their relationship with the exposure and outcomes; history of stroke; injury severity (length of hospital stay, discharge status, independent survival risk ratio); healthcare provider characteristics (total physicians, hospitals, hospitals with trauma services, hospitals with neurological services, and beds per 100 000 people); and pre-TBI statin use. The mortality and stroke models also included anticoagulant, antiplatelet, and β-blocker use in the month due to their relationship with statin use and mortality and stroke. [19] [20] [21] [22] In addition, the model assessing any stroke included history of any stroke in the 6 months prior to TBI. Similarly, the models assessing ischemic and hemorrhagic stroke included history of ischemic and hemorrhagic stroke, respectively, 6 months prior to TBI. Finally, the depression model also included monthly β-blocker use.
Secondary analyses on associated morbidities were conducted after excluding beneficiaries with less than 12 months of observation time following TBI. This was done to allow beneficiaries greater time to experience or be diagnosed with TBI sequelae events. Sensitivity analyses were conducted by including inverse probability of treatment weights (IPTW). Inverse probability of treatment weights help decrease bias caused by nonrandom assignment of treatment. 25 IPTW were constructed by modeling any post-TBI statin use following hospitalization discharge as a function of the risk factors (baseline and time-varying) for the outcomes of interest. The risk factors included the covariates mentioned previously for each model. The final sensitivity analysis models included their IPTW in addition to their individual covariates IPTW.
Relative risks (RR) and 95% confidence intervals (CIs) were reported. All analyses were performed using SAS (Cary, North Carolina). This study was approved by the Institutional Review Board of the University of Maryland, Baltimore.
RESULTS
A total of 116 170 Medicare beneficiaries 65 years of age and older were hospitalized with a TBI from 2006 through 2010. Of these, 110 500 had six months of observation time prior to TBI and continuous Medicare parts A, B, and D coverage following TBI. The final sample comprised 100 515 beneficiaries who survived TBI hospitalization. Approximately 50% (50 173) of these beneficiaries used statins prior to and/or following TBI (see Figure 1 ).
The study sample was predominately white (87%) and female (65%) and the mean age of the sample was 81 (SD: 8.1) years. Statin users were more likely to have cardiovascular disease (P < .0001). While 93% of statin users had hyperlipidemia, the majority (57%) of nonusers also had hyperlipidemia (P < .0001) (see Table 1 ). Statin use remained stable throughout the study period. The most commonly used statin was simvastatin, followed by atorvastatin while fluvastatin was the least used statin (results not shown).
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A total of 41 650 beneficiaries died following TBI hospitalization discharge, of whom 8507 died within 30 days, 3348 died after 30 days but within 60 days, and 2439 died after 60 days but within 90 days of hospitalization discharge. A total of 9420 beneficiaries developed ischemic stroke, 3841 had hemorrhagic stroke, 10 748 had incident depression, and 14 907 had incident ADRD.
Adjusted generalized estimating equations models showed that post-TBI statin use of any kind was associated with lower mortality following TBI-hospitalization discharge. The greatest difference is seen in 30-day mortality following TBI (see Table 2 ).
Adjusted analysis of associated morbidities indicated that any statin use was associated with a lower risk of any stroke (RR, 0.86; 95% CI, 0.81-0.91), ischemic stroke (RR, 0.91; 95% CI, 0.85-0.96), hemorrhagic stroke (RR, 0.75; 95% CI, 0.67-0.83), depression (RR, 0.85; 95% CI, 0.79-0.90), and ADRD (RR, 0.77; 95% CI, 0.73-0.81). Both atorvastatin and simvastatin use were associated with a lower risk of all associated morbidity outcomes (see Table 3 ). Secondary analysis among beneficiaries with at least 12 months of observation time following TBI showed similar associations (see Table 4 ).
Sensitivity analyses incorporating IPTW also showed similar results for mortality and associated morbidities (see Supplemental Digital Content Table 1 
DISCUSSION
This is the first study to investigate the relationship of statin use following TBI and mortality and associated morbidities post-TBI hospitalization discharge. In this sample of older Medicare beneficiaries with TBI, statin use following injury was associated with major decreases in 30-day, 60-day, and 90-day mortality, as well as a reduction in ischemic and hemorrhagic stroke, incident Abbreviations: N/A, not applicable (estimate is too small and unreliable); ADRD, Alzheimer's disease and related dementias. a Adjusted for sociodemographic characteristics (age, race, sex, county-level income, low-income subsidy status, region); cardiovascular disease (congestive heart failure, acute myocardial infarction, ischemic heart disease, valvular heart disease, hyperlipidemia, hypertension); diabetes; ADRD; count of Chronic Condition Data Warehouse chronic conditions excluding cardiovascular disease and ADRD and diabetes; injury severity (length of hospital stay, discharge status, independent survival risk ratio); medication use in month (anticoagulant use, antiplatelet use, β-blocker); healthcare provider characteristics per 100 000 population (physicians, hospitals, hospitals with trauma services, hospitals with neurological services, beds); and pre-traumatic brain injury statin use. Abbreviation: ADRD, Alzheimer's disease and related dementias. a All models adjusted for sociodemographic characteristics (age, race, sex, county-level income, low-income subsidy status, region); cardiovascular disease (congestive heart failure, acute myocardial infarction, ischemic heart disease, valvular heart disease, hyperlipidemia, hypertension); diabetes; ADRD; count of Chronic Condition Data Warehouse chronic conditions excluding cardiovascular disease and ADRD and diabetes; injury severity (length of hospital stay, discharge status, independent survival risk ratio); healthcare provider characteristics per 100 000 population (physicians, hospitals, hospitals with trauma services, hospitals with neurological services, beds); and pre-traumatic brain injury (TBI) statin use. Stroke models also included medication use in month (anticoagulant use, antiplatelet use, β-blocker) and history of any stroke, ischemic stroke, or hemorrhagic stroke 6 months prior to TBI. Depression models also included β-blocker use in month.
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depression, and ADRD. Specifically, atorvastatin and simvastatin were associated with significant decreases in all TBI sequelae outcomes. The decrease in mortality and associated morbidities may be due to statins' anti-inflammatory properties. Furthermore, these statins were the most commonly used statins. These results are especially encouraging because statin users were more likely to have illnesses prior to TBI, such as history of stroke, and can be viewed as having higher risk of mortality and associated morbidities. However, even with a history of stroke and other cardiovascular disease, these beneficiaries witnessed lower mortality and TBI sequelae events. One study previously examined the association with statin discontinuation during hospitalization and found that statin discontinuation among preinjury statin users was associated with an approximately 4-fold higher mortality than among patients who continued statin use during hospitalization. 26 However, this relationship was not significant (P = .055), potentially due to their small sample size (n = 61). 26 Another study of 39 patients with TBI, of whom 19 received statins for 10 days following TBI, assessed the impact of statin on inflammation, rather than mortality. The results of this study indicated that statin use decreased inflammation following TBI. 27 This is also the first study to investigate the relationship between statin use following TBI and TBI sequelae, including stroke, depression, and ADRD. The results indicate that any statin use was associated with 9% lower risk of ischemic stroke, 25% lower risk of hemorrhagic stroke, and 14% lower risk of any stroke, controlling for pre-TBI comorbidity. Atorvastatin and simvastatin were the only statins associated with lower risk of both ischemic and hemorrhagic stroke. One study among older Medicare beneficiaries compared rates of ischemic stroke and hemorrhagic stroke prior to and following TBI and found that rate of ischemic stroke following TBI was 1.3 times greater than that pre-TBI and the rate of hemorrhagic stroke following TBI was 6.5 times greater than that pre-TBI. 6 The greater increase in the rate of hemorrhagic stroke makes the findings from this study especially encouraging as statin use is associated with significantly lower risk of hemorrhagic stroke. It should be noted that statins are often used among stroke Abbreviation: ADRD, Alzheimer's disease and related dementias. a All models adjusted for sociodemographic characteristics (age, race, sex, county-level income, low-income subsidy status, region); cardiovascular disease (congestive heart failure, acute myocardial infarction, ischemic heart disease, valvular heart disease, hyperlipidemia, hypertension); diabetes; ADRD; count of Chronic Condition Data Warehouse chronic conditions excluding cardiovascular disease and ADRD and diabetes; injury severity (length of hospital stay, discharge status, independent survival risk ratio); healthcare provider characteristics per 100 000 population (physicians, hospitals, hospitals with trauma services, hospitals with neurological services, beds); and pre-traumatic brain injury (TBI) statin use. Stroke models also included medication use in month (anticoagulant use, antiplatelet use, β-blocker) and history of any stroke, ischemic stroke, or hemorrhagic stroke 6 months prior to TBI. Depression models also included β-blocker use in month.
patients; the results of this study suggests that statins also may be beneficial for individuals at risk of stroke following TBI. All statins except fluvastatin were associated with lower incident depression and ADRD following TBI. These statins were all associated with at least 15% lower incident depression and at least 17% lower incident ADRD. One study examined the rates of depression among older Medicare beneficiaries with TBI and found the rates of depression almost doubled following TBI. 7 Furthermore, moderate and severe TBIs also have been linked to 2.3 and 4.5 times increase in the risk of ADRD, respectively, as TBI can hasten the natural cognitive decline among older adults. 28, 29 The increase in the risk of depression and ADRD following TBI is partially due to chronic neuroinflammation, which is a common physiological consequence of TBI. 4, 5, 30 However, it should be acknowledged that the association between TBI and late life neurodegenerative conditions such as ADRD has been questioned, requiring further investigation of the association between TBI and ADRD. 31 While this is the first study to investigate the relationship between statin use following TBI and post-TBI hospitalization discharge mortality and associated morbidities, it is not without limitations. Primarily, the mortality observed in this study is all-cause mortality rather than mortality related to complications of TBI. The CCW data do not indicate cause of death. However, we examined multiple mortality models in which the relationship between 30-day, 60-day, and 90-day mortality and statin use was assessed. It is possible that 30-day mortality is more likely to be TBI-specific than other mortality models and it is in this model that beneficiaries witnessed the greatest difference in mortality. In addition, it is possible that beneficiaries discontinued statin use during end-of-life care and died a few months following discontinuation. This analysis classifies such beneficiaries as nonusers at the time of death, potentially artificially inflating the impact of statin use on mortality. Similarly, statins could have only been prescribed to less severe TBI patients with a greater anticipated life expectancy, as compared with more severe patients with a decreased Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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life expectancy. This healthy user effect may have biased the results as healthy statin users were potentially compared with less healthy nonusers. 32 Finally, potentially lifesaving medications given during hospitalization or medications taken over the counter, such as nonsteroidal anti-inflammatory drugs, are not available in the data and could not be accounted for in the analysis. Furthermore, other medications available in the data that could impact associated outcomes were not included in the analysis. However, this was done to build parsimonious models. For instance, antidepressants were not included because they are correlated with depression, which was included as a count of comorbidities.
Another limitation is that depression is episodic as beneficiaries may experience relapses from remission; therefore, they may be misclassified as depressed or nondepressed. 33 To counter this limitation, in the examination of depression as an outcome, beneficiaries with a prior CCW diagnosis of depression were excluded. This helped in creating a cleaner cohort in which beneficiaries did not have prevalent depression and therefore mitigating possible misclassification. Similarly, in the examination of ADRD as an outcome, beneficiaries with prior ADRD were excluded from the analysis. However, it was not possible to exclude beneficiaries with undiagnosed depression and ADRD prior to TBI.
There are multiple strengths to this study. The longitudinal study design allowed for the assessment of a time-varying exposure, which mimics a "real-world" setting. This study also was able to differentiate the impact between statins. In addition, this study was able to incorporate several covariates by linking CCW and Area Health Resource File data. Including sociodemographic, health, drug utilization, and geographical covariates helped reduce confounding. Furthermore, sensitivity analysis with IPTW was incorporated to reduce selection bias.
While this study had methodological strengths, the most salient strength of this study is that it provides precious information regarding statin use and outcomes following TBI. No prior study has investigated the relationship between statin use following TBI and mortality and associated morbidities. Previous animal studies have examined secondary endpoints such as neuroinflammation and other biomarkers and have found that statin use following TBI decreases neuroinflammation and improves neurological function following injury. [34] [35] [36] [37] [38] [39] [40] [41] [42] It should be noted that some previous human clinical trials have failed after encouraging results from animal studies, potentially due to inadequate biomarkers. 43 However, this translational retrospective study sets the platform for human clinical trial by examining primary endpoints. Unlike previous studies, human clinical trials examining pharmacologic treatments for TBI following encouraging animal research, future clinical trials investigating the impact of statins on TBI patients can utilize the information gained from this large observational study.
This large-scale study of older Medicare beneficiaries highlights the potential of statins to treat mortality and associated morbidities associated with TBI. The study found that atorvastatin and simvastatin are not only the most commonly used statins but also the only two statins that were associated with a significant risk lowering in all outcomes observed. Findings provide valuable information for clinicians treating older adults with TBI. As this study finds, the majority of nonstatin users had also had hyperlipidemia and clinicians can consider, when appropriate, statin use among elderly TBI patients with and without hyperlipidemia. While this study provides a foundation, more research is required to investigate mortality and associated morbidities associated with TBI in order to corroborate these results. Future research can incorporate non-TBI patients to clarify the benefits of statins specifically to TBI. Furthermore, future research can examine other salient associated morbidities following TBI to provide a clearer sense of range of sequelae associated with TBI.
